文献速递白血病

地西他滨表观遗传预处理后阿糖胞苷治疗老年急性髓系白血病的2期研究

Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
PubMed 文献 · Am J Hematol · 2024-01-22

这项2期试验纳入44例初治老年急性髓系白血病患者(中位年龄76岁),采用地西他滨20 mg/m2静脉注射5天后续阿糖胞苷100 mg/m2持续静脉输注5天的诱导方案,1或2个疗程。完全缓解/完全缓解伴血细胞计数不完全恢复(CR/CRi)率达59%(可评估患者66.7%),中位总生存期10.7个月,4周和8周死亡率分别为2.3%和9.1%。

要点

  • 44例初治老年AML患者接受地西他滨表观遗传预处理后阿糖胞苷诱导,CR/CRi率59%。
  • 不良细胞遗传学患者中21例有14例(66.7%)达CR,7例可评估TP53突变者中6例达CR。
  • 4周和8周死亡率分别为2.3%和9.1%,中位总生存期10.7个月。

核心结论

  • 结果提示地西他滨表观遗传预处理后阿糖胞苷可考虑作为老年AML患者的一线治疗选择。

研究设计与样本

  • 2期临床试验,纳入44例初治老年急性髓系白血病患者,中位年龄76岁。
  • 诱导方案为地西他滨20 mg/m2静脉注射5天后续阿糖胞苷100 mg/m2持续静脉输注5天,共1或2个疗程。
  • 试验注册号NCT01829503。

主要发现

  • 44例患者中26例(59%)达CR/CRi,可评估患者中达CR/CRi比例为66.7%。
  • 21例不良细胞遗传学患者中14例(66.7%)达CR,7例可评估TP53突变患者中6例达CR。
  • 4周死亡率为2.3%,8周死亡率为9.1%,中位总生存期为10.7个月。

临床怎么用

  • 作者认为地西他滨表观遗传预处理后阿糖胞苷可考虑作为老年AML患者的一线治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) in older patients has a poor prognosis, low complete remission (CR) rates, and poor overall survival (OS). Preclinical studies have shown synergistic effects of epigenetic priming with hypomethylating agents followed by cytarabine. Based on these data, we hypothesized that an induction regimen using epigenetic priming with decitabine, followed by cytarabine would be effective and safe in older patients with previously untreated AML. Here, we conducted a phase 2 trial in which older patients with previously untreated AML received an induction regimen consisting of 1 or 2 courses of decitabine 20 mg/m2 intravenously (IV) for 5 days followed by cytarabine 100 mg/m2 continuous IV infusion for 5 days. Forty-four patients (median age 76 years) were enrolled, and CR/CRi was achieved by 26 patients (59% of all patients, 66.7% of evaluable patients). Fourteen of 21 (66.7%) patients with adverse cytogenetics achieved CR including six out of seven evaluable patients with TP53 mutations. The 4- and 8-week mortality rates were 2.3% and 9.1%, respectively, with median OS of 10.7 months. These results suggest epigenetic priming with decitabine followed by cytarabine should be considered as an option for first-line therapy in older patients with AML. This trial was registered at www.clinicaltrials.gov as # NCT01829503.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Im A, Quann K, Agha M, et al. Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients. Am J Hematol. 2024. PMID: 38258329. doi:10.1002/ajh.27212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。